Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) - Shen, Lin; Li, Jin; Xu, Jianming; Pan, Hongming; Dai, Guanghai; Qin, Shukui; Wang, Liwei; Wang, Jinwan; Yang, Zhenzhou; Shu, Yongqian; Xu, Ruihua; Chen, Lei; et al. (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015)
Keywords: Abdominal Surgery; Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asian Continental Ancestry Group; Bevacizumab; Cancer Research; Capecitabine; Cisplatin - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophagogastric Junction - pathology; Female; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Gastric cancer; Gastroenterology; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original; Original Article; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Surgical Oncology; Treatment Outcome; Gastric adenocarcinoma; Bevacizumab